{"id":"https://openalex.org/W4361815484","doi":"https://doi.org/10.1158/1078-0432.c.6529476","title":"Data from Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy","display_name":"Data from Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361815484","doi":"https://doi.org/10.1158/1078-0432.c.6529476"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6529476","doi":"https://doi.org/10.1158/1078-0432.c.6529476","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6529476","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6529476","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075144810","display_name":"Eduardo Huarte","orcid":"https://orcid.org/0000-0001-7498-7547","observed_orcids":["https://orcid.org/0000-0001-7498-7547"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eduardo Huarte","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041497357","display_name":"Roddy S. O\u2019Connor","orcid":"https://orcid.org/0000-0001-5645-4544","observed_orcids":["https://orcid.org/0000-0001-5645-4544"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roddy S. O'Connor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055912368","display_name":"Michael T. Peel","orcid":"https://orcid.org/0000-0002-4599-6767","observed_orcids":["https://orcid.org/0000-0002-4599-6767"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael T. Peel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014279022","display_name":"Selene Nu\u00f1ez-Cruz","orcid":"https://orcid.org/0000-0002-4538-957X","observed_orcids":["https://orcid.org/0000-0002-4538-957X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Selene Nunez-Cruz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110109207","display_name":"John M. Leferovich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Leferovich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080610604","display_name":"Ashish Juvekar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ashish Juvekar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087018979","display_name":"Yan\u2010ou Yang","orcid":"https://orcid.org/0000-0002-9315-5639","observed_orcids":["https://orcid.org/0000-0002-9315-5639"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan-ou Yang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lisa Truong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lisa Truong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112448674","display_name":"Taisheng Huang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Taisheng Huang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103747728","display_name":"Ahmad Bilal Naim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ahmad Naim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086683313","display_name":"Michael C. Milone","orcid":"https://orcid.org/0000-0002-1580-9844","observed_orcids":["https://orcid.org/0000-0002-1580-9844"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael C. Milone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101762218","display_name":"Paul A. Smith","orcid":"https://orcid.org/0000-0003-3194-9000","observed_orcids":["https://orcid.org/0000-0003-3194-9000"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul A. Smith","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/itacitinib","display_name":"itacitinib","score":1.0},{"id":"https://openalex.org/keywords/jak1-inhibitor","display_name":"JAK1 inhibitor","score":0.9769999980926514},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.9869999885559082},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.9940000176429749},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.8169999718666077},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.6200000047683716},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.9729999899864197},{"id":"https://openalex.org/keywords/cd19-car-t-cells","display_name":"CD19 CAR T cells","score":0.8820000290870667},{"id":"https://openalex.org/keywords/gd2-car-t-cells","display_name":"GD2 CAR T cells","score":0.8429999947547913},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/car-t-cell-proliferation","display_name":"CAR-T cell proliferation","score":0.7630000114440918},{"id":"https://openalex.org/keywords/prophylaxis","display_name":"prophylaxis","score":0.7070000171661377}],"concepts":[{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.70780348777771},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5689254999160767},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.5600911974906921},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5271111130714417},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.4634343087673187},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4557506740093231},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4548247158527374},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.4180406332015991},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4138810336589813},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4009355902671814},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.3980083465576172},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3822193741798401},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.31372788548469543},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.17822718620300293},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6529476","doi":"https://doi.org/10.1158/1078-0432.c.6529476","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6529476","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6529476","doi":"https://doi.org/10.1158/1078-0432.c.6529476","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6529476","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9907000064849854,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3091701886","https://openalex.org/W2987104954","https://openalex.org/W4391602229","https://openalex.org/W4310163450","https://openalex.org/W4412628997","https://openalex.org/W3001033951","https://openalex.org/W4417010102","https://openalex.org/W4389231206","https://openalex.org/W4407977136","https://openalex.org/W4408492559"],"abstract_inverted_index":{"AbstractPurpose:":[0],"T":[1,185,218],"cells":[2,186],"engineered":[3],"to":[4,75,119],"express":[5],"a":[6,12,37,52,112,210,222],"chimeric":[7],"antigen":[8],"receptor":[9],"(CAR)":[10],"are":[11,73],"promising":[13],"cancer":[14],"immunotherapy.":[15],"Such":[16],"targeted":[17],"therapies":[18],"have":[19],"shown":[20],"long-term":[21],"relapse-free":[22],"survival":[23],"in":[24,71,100,101,104,129,131,133,136,176,178],"patients":[25],"with":[26,45],"B-cell":[27],"leukemia":[28],"and":[29,64,97,103,121,135,173,221],"lymphoma.":[30],"However,":[31],"cytokine":[32,60,98],"release":[33],"syndrome":[34],"(CRS)":[35],"represents":[36],"serious,":[38],"potentially":[39],"life-threatening":[40],"side":[41],"effect":[42,85],"often":[43],"associated":[44],"CAR":[46,92,168,217,235],"T-cell":[47,93,169,236],"therapy.":[48],"CRS":[49,72,130,232],"manifests":[50],"as":[51,209],"rapid":[53],"(hyper)immune":[54],"reaction":[55],"driven":[56],"by":[57,196,234],"excessive":[58],"inflammatory":[59],"release,":[61],"including":[62],"IFN\u03b3":[63],"IL6.":[65],"Experimental":[66],"Design:":[67],"Many":[68],"cytokines":[69,127],"implicated":[70,128],"known":[74],"signal":[76],"through":[77],"the":[78,84,214],"JAK-STAT":[79],"pathway.":[80],"Here":[81],"we":[82,140],"study":[83],"of":[86,125,164,183,216,227,231],"blocking":[87],"JAK":[88],"pathway":[89],"signaling":[90],"on":[91],"proliferation,":[94],"antitumor":[95,161,181],"activity,":[96],"levels":[99,124],"vitro":[102,134],"vivo":[105,137,179],"models.":[106,138],"Results:":[107],"We":[108],"report":[109,142],"that":[110,143,148,205],"itacitinib,":[111],"potent,":[113],"selective":[114],"JAK1":[115,151],"inhibitor,":[116],"was":[117,194],"able":[118],"significantly":[120,157],"dose-dependently":[122],"reduce":[123],"multiple":[126],"several":[132],"Importantly,":[139],"also":[141],"at":[144],"clinically":[145],"relevant":[146],"doses":[147],"mimic":[149],"human":[150,167],"pharmacologic":[152],"inhibition,":[153],"itacitinib":[154,198,206,228],"did":[155],"not":[156],"inhibit":[158],"proliferation":[159],"or":[160],"killing":[162],"capacity":[163],"three":[165],"different":[166],"constructs":[170],"(GD2,":[171],"EGFR,":[172],"CD19).":[174],"Finally,":[175],"an":[177],"model,":[180],"activity":[182],"CD19-CAR":[184],"adoptively":[187],"transferred":[188],"into":[189],"CD19+":[190],"tumor-bearing":[191],"immunodeficient":[192],"animals":[193],"unabated":[195],"oral":[197],"treatment.":[199],"Conclusions:":[200],"Together,":[201],"these":[202],"data":[203],"suggest":[204],"has":[207,238],"potential":[208],"prophylactic":[211],"agent":[212],"for":[213,229],"prevention":[215,230],"cell\u2013induced":[219],"CRS,":[220],"phase":[223],"II":[224],"clinical":[225],"trial":[226],"induced":[233],"therapy":[237],"been":[239],"initiated":[240],"(NCT04071366).":[241]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}